With a market valuation of...
Alopex Gold, a gold mining company with significant operations in Greenland, has listed on the Toronto Stock Exchange (TSV).
With a market valuation of $24,796,250, Alopex will be focusing on exploration at its Nalunaq mine and Tartoq gold properties across Greenland.
“I am very pleased to announce the successful completion of our IPO on the TSXV and I would like to take this opportunity to thank our existing shareholders for their continuing support and to welcome our new shareholders; this is an exciting and critical phase in the development of our business.” Eldur Olafsson, the CEO of Alopex said.
“The management team and I will now focus on progressing our projects in Greenland, as we seek to further de-risk our Nalunaq and Tartoq projects towards commercial production. With our exciting summer 2017 work program about to kick off, I look forward to updating the market as to our progress in the coming months.”
Alopex Gold is a Greenland based explorer, with a key focus on the identification, acquisition, exploration and development of gold properties in Greenland.
Nalunaq is the company’s flagship project, which is a significantly advanced exploration property.
Alopex’s goal is to explore and develop in order to expand the existing resources at Nalunaq mine whilst simultaneously exploring other known gold occurrences in South Greenland. Some of these are close to Nalunaq and may be similar in mineralisation style. It is envisaged that some of these properties will form a ‘pipeline’ of projects at different levels of development that will deliver the company a sustainable supply of resources for exploitation.
In the mining and exploration space, opportunity can present itself in many forms. Greenland is a country rich with mining and mineral opportunity and it is the job of the Ministry of Mineral Resources to present that potential to the major players of the mining and exploration world.
“The mineral potential of Greenland is incredible,” says Henrik Stendal, Chief Geologist for THE MMR.